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ABSTRACT: Alzheimer's disease is on the rise around the globe and is ranked sixth in the United States 
as the leading cause of death. It is a progressive neurodegenerative disease and the main causes of 
dementia. It is often characterized by symptoms such as lack of memory, agitation, restlessness, changes 
in personality, inability to perform everyday tasks, and impairment of speech. There are two forms of 
Alzheimer's disease: early onset of Alzheimer's disease occurring before 65 years of age, manifesting in 
5-10% of the population, and late-onset of Alzheimer's disease manifesting after 65 years of age. In this 
study, the role of single nucleotide polymorphism in Alzheimer's disease using genome-wide association 
studies was investigated. Further, mutations underlying early onset of Alzheimer's disease were analyzed 
and it was found that mutations in the six genes APP, PSEN1, PSEN2, MAPT, GRN and PRNP resulted 
in the structural and functional protein modifications. These altered amino acids in early onset of 
Alzheimer's disease contribute to its pathogenesis. A single change in these genes is inherited in an 
autosomal dominant manner and might lead to early onset of Alzheimer's disease, however sporadic 
cases have also been identified. 
Keywords: Alzheimer's disease; Single nucleotide polymorphism; EOAD; Amyloid; Tau. 
1. INTRODUCTION 
Alzheimer’s disease is the leading cause of dementia. When a person younger than 65 years of age 
develops Alzheimer’s, he is said to be suffering from Early Onset of Alzheimer’s Disease (EOAD). EOAD 
can be of two types: Common Alzheimer disease (progresses similarly to Late Alzheimer), and Familial 
Alzheimer (it is controlled by a variety of genes) [1, 2]. Alzheimer disease affects the brain of an 
individual, the damage begins at the hippocampal region and the entorhinal region, located in the temporal 
lobe and responsible for memory formation. As the number of dead healthier neurons increases, the disease 
progresses to additional parts of the brain and the brain tissue further degenerates interfering with trivial 
processes of swallowing, walking, memorizing and talking etc. This loss of brain tissue is attributed to the 
deposition of abnormal amounts of extracellular amyloid and intracellular tau proteins [3]. 
These abnormal depositions are a result of single nucleotide polymorphisms (SNPs) in DNA 
nucleotides. SNPs causing non-synonymous mutations (missense or non-sense) lead to the production of 
protein products which are entirely different from the original protein in terms of charge, size and overall 
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effect. This modified amino acid sequence leads to improper cleavage of the APP protein, disrupted 
cleavage activity by PSEN 1 and 2 and hyper-phosphorylation of MAPT protein [4, 5]. These mutations 
ultimately lead to the pathophysiology of Alzheimer disease which includes the presence of intracellular 
tau filaments, extracellular beta-amyloid plaques and inflammation [6, 7]. Symptoms of EOAD include 
dementia – the gradual loss of cognition, memory and judgement, loss of ability to function, behavioural 
and personality changes, subtle memory loss at first and then worsening of memory, difficulty in 
recognizing people, inability to perform daily chores such as, cooking meal, doing laundry etc. restlessness, 
agitation and loss of communication skills [8]. 
2. MATERIALS AND METHODS 
Genetics Home Reference (GHR), a National Library for Medicine, consisting of information 
about genetic diseases was used. Using GHR site Pathogenic alleles responsible for EOAD were 
analyzed and the function of the proteins encoded by these genes and the families they belong to were 
investigated and recorded.  
Then, using the NCBI-gene site, transcript mutation and rsIDs were identified. NCBI-SNP 
database was used to study the codon change and amino acid sequence changes were identified. The data 
are recorded in the form tables (Table 1 and Table 2). 
 
Table 1. Table showing genes responsible for EOAD, functions of the proteins they encode for and their protein families. 
Gene Protein family function Common function 
APP 
Proteins of this family are important for nervous 
system development (neuron migration, 
synaptogenesis, neurite outgrowth and axonal 
pathfinding). App proteins can function using 
multiple-modes, these can function as ligands via their 
secreted fragments or as cell surface proteins carrying 
signal transduction and adhesion. 
All the three members of APP gene family, 
APP, APLP1, APLP2 associate with NMDA 
receptor and enhance its cell surface 
expression. NMDA receptors are important in 
synaptic plasticity and memory.  
PSEN 1 
Presenilins function in developmental signaling, 
apoptosis, and processing amyloid beta proteins. 
They form catalytic units of gamma secretase. 
PSEN 2 Same as PSEN 1 Same as PSEN 1 
MAPT 
Members of the family function in binding to and 
stabilizing microtubules. 
All of them are associated with microtubules 
and make them stable. 
GRN 
All the members of the family are secreted proteins 
and function in cell growth and proliferation. 
They might be inhibitors, stimulators or both 
however, all of them have a function in cell growth. 
PRNP 
Prion family of proteins function in early 
embryo-genesis. 
Two proteins of the family have a neuroprotective 
function. However, one member of the protein 
family is present in the testes. 
 























Hydrophobic valine having a longer 
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by hydrophobic valine whose 
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hydrocarbon chain is shorter as 
compared to it. 
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rs63750734 V715M V691M 
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hydrophobic methionine having a 
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Non-polar alanine is replaced by non-








Non-polar alanine is replaced by a 








Positively charged glutamic acid is 
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rs1057518919 F105C F101C 
Aromatic amino acid is replaced by 













Aromatic amino acid tyrosine is 




rs63750730 T116N T112N 
Polar threonine containing a hydroxyl 
group is replaced by polar asparagine 





rs63751272 E120D E116D 
Negatively charged glutamic acid is 
replaced by another negatively 
charged aspartic acid whose side 







Polar asparagine having an amide in 
its side chain is replaced by polar 







c.254C>T rs63750048 A85V 
Hydrophobic alanine is replaced by 
hydrophobic valine having a longer 
side chain. 
Pathogenic 
c.364A>C rs63749851 T122P 
Polar uncharged threonine is replaced 
by polar uncharged proline having a 
Pathogenic 
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ring in its side chain. 
c.365C>G rs28936380 T122R 
Polar uncharged amino acid is 
replaced by positively charged 
arginine. 
Pathogenic 
c.389C>T rs63750197 S130L 
Polar uncharged amino acid is 
replaced by a non-polar amino acid. 
Pathogenic 
c.422A>T rs63750215 N141I 
Polar uncharged amino acid amino 
acid is replaced by non-polar amino 
acid. 
Pathogenic 
c.717G>A rs63749884 M239I 
Sulfur containing non-polar 
methionine is replaced by non-polar 
isoleucine. 
Pathogenic 
c.1289C>T rs63750666 T430M 
Polar uncharged threonine is replaced 
by sulfur containing non-polar 
methionine. 
Pathogenic 
c.1316A>C rs63750110 D439A 
Negatively charged amino acid is 
replaced by non-polar alanine. 
Pathogenic 
GRN 
c.2T>C rs63751006 M1T 
Non-polar amino acid gets replaced 
by a polar amino acid. 
Pathogenic 
c.26C>A rs63751243 A9D 
Non-polar alanine gets replaced by 
polar aspartate. 
Pathogenic 
c.26C>T rs63751243 A9V 
Non-polar alanine is replaced by non-
polar valine having a longer side 
chain. 
Pathogenic 
c.373C>T rs63750077 Z125Ter 




c.305C>T rs74315401 P102L 
Non-polar proline having secondary 
imine is replaced by a non-polar 
amine containing leucine. 
Pathogenic 
c.385A>G rs1799990 M129V 
Non-polar amino acid containing 
sulphur gets replaced by a non-polar 
amino acid having a hydrocarbon side 
chain. 
Pathogenic 
c.435T>G rs80356710 Y145Ter 
Early termination fails to incorporate 
tyrosine. 
Pathogenic 
c.350C>T rs74315402 A117V 
Non-polar alanine is replaced by non-




3. RESULTS AND DISCUSSION 
The present study illustrated that mutations in primarily three genes is responsible for early onset of 
Alzheimer’s Disease: APP, PSEN1 and PSEN2 (Table 2). 
3.1. APP gene  
APP gene present on the long arm (q) of chromosome 21 (21q21.3) encodes for APP protein, which is 
a type 1 membrane protein (integral membrane protein having its amino- terminal facing the extracellular 
side) [9]. This protein has two domains; larger extracellular and smaller intracellular. Two cleavage events 
occur in these proteins: β-secretase cleavage occurs in the extracellular domain and γ-secretase cleavage 
which occurs in the intracellular domain. During amyloidogenic processing of APP, β-secretase or beta site 
cleaving enzyme (BACE) cleaves the amyloid beta-protein at its N-terminus to produce soluble amyloid 
protein (sAPPβ) and a 99 amino acid C-terminal residue (C99) (Fig. 1). Subsequently, γ-secretase (membrane 
protein) along with presenilin (catalytic component) cleaves the C99 fragment to produce an amyloid beta- 
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protein (Aβ) and APP intracellular domain (AICD) [10, 11]. The cleavage sites for γ-secretase are diverse and 
therefore, Aβ having different C-termini are produced ranging from, Aβ1- 40 (Aβ40), Aβ1- 42. The function 
of APP in the central nervous system is neural proliferation, migration, synaptogenesis and neural plasticity. 




Figure 1. Amyloid processing of APP protein. 
 
More than 25 APP mutations that can result in EOAD have been identified. These mutations in the 
APP gene might result in an augmented quantity of β-peptide amyloid. Another possibility can be that these 
mutations which modify the charge or the length of the side chain, ultimately produce a protein having  
a totally different conformation e.g., a longer sticky peptide which accumulates in the brain to form amyloid 
plaques. Hence, Aβ40 to Aβ42 ratio goes down producing Aβ42 predominantly in the cell. This form of 
amyloid beta- protein is neurotoxic since it leads to the formation of amyloid plaques which deposit 
extracellularly and lead to the death of brain tissue [4, 12, 13]. 
3.2. PSEN 1 (Presenilin 1) 
This gene is present on the long arm (q) of chromosome 14 (14q24.2) PSEN 1 gene product forms an 
indispensable part of γ-secretase which functions in cleaving of amyloid beta protein [14, 15]. For PSEN 1 
gene more than 62 mutations were identified. A relatively common variation positions are polar asparagine 
having an amide in its side chain at positions 131 and 135 is replaced by polar serine having a hydroxyl group 
are suspected to take place at sites which directly interact with amyloid protein for its cleavage. It is also 
reported that PSEN 1 mutations result in the production of an abnormal protein called presenilin-1[16, 17]. 
This faulty presenilin 1 protein obstructs the role of the γ-secretase complex; hence, the production of APP is 
altered and excess longer, toxic amyloid-β peptides are produced [18]. These then bind together into clumps 
called amyloid plaques in the brain eventually leading to death of nerve cells and steady symbols and 
indications of EOAD. 
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3.3. PSEN 2 (Presenilin 2) 
This gene is present on the long arm (q) of chromosome 1 (1q42.13) [19]. PSEN 2 gene product is also 
 a prime component of γ-secretase along with PSEN1. Presenilin 2 is involved in the amyloid precursor protein 
processing in the brain. Presenilin 2 is reported to break amyloid precursor protein into smaller peptides; soluble 
amyloid precursor protein (sAPP) and amyloid beta peptide. Mutations, where a polar uncharged amino acid like 
asparagine is replaced by a non-polar isoleucine amino acid alters the activity of γ-secretase in the region of 
protein which interacts with amyloid protein to cleave it, causing impaired amyloid precursor protein processing 
and overproduction of amyloid beta peptide. Consequently, this results in deposition of amyloid plaques and 
neurons’ death. All these mutations lead to inappropriate cleaving amyloid protein and produce Aβ42 in 
excessive amounts, as a consequence of which extracellular plaques get deposited [17, 19, 20]. 
3.4. MAPT 
Microtubule associated protein Tau (MAPT) gene present on the long arm(q) of chromosome 17 
(17q21) encodes for tau protein [21]. Tau protein interacts with tubulin proteins and helps in their assembly 
into microtubules. Microtubule assembly by tau, which is a phosphoprotein is dependent upon the level of 
phosphorylation. Under normal physiological conditions, an adult human brain has 2-3 moles of phosphate/ 
mole of tau protein. However, during Alzheimer’s tau protein gets 3-4 times hyper-phosphorylated as 
compared to its normal levels; it is during this state that tau proteins detach from microtubules and attach to 
form tangled threads inside neurons [22]. Inside neurons, there are 6 isoforms of this protein, three of these 
isoforms have 3 repeating segments in microtubule-binding domain whereas rest 3 proteins have 4 repeating 
segments in the microtubule-binding domain. Neurons have a 1:1 ratio of 3-repeats isoforms and 4-repeats 
isoforms, this ratio is crucial in maintaining normal cellular function. MAPT gene can therefore act as a potent 
risk factor for development of EOAD [23, 24]. 
3.5. GRN 
GRN gene is present on the long arm (q) of chromosome 17, somewhere around the MAPT gene. GRN 
gene is responsible for providing instructions to encode the progranulin protein (PGRN) [25]. The progranulins 
can be further cleaved into their active forms granulins (GRN) in seven different ways. GRN is a secreted 
protein, therefore it establishes its function outside the cell, it is responsible for cell-cell signalling, acts as a 
growth factor, helps in cell proliferation and wound repair. Loss of function mutations in one of the heterozygous 
combination of alleles leads to haploinsufficient gene product of a single allele in a diploid locus and is unable to 
generate threshold level of gene products [26]. As a result, such haploinsufficient individuals only have half the 
functional progranulin protein and hence, only half the functional granulins. It has been suspected that deficiency 
in this protein leads to the build-up of TDP-43 (TAR DNA binding protein). TDP-43 forms aggregate inside the 
nucleus, disrupts cellular functions and leads to cell death [27, 28, 29]. 
3.6. PRNP 
Prnp gene, present on chromosome 20 encodes for prion proteins (PrP) the proposed functions of this 
gene are neuroprotection, buffering of copper and zinc ions in the synaptic cleft, myelin sheath maintenance 
in PNS, it also prevents the formation of reactive oxygen species (ROS) formed as a result of copper-mediated 
redox reactions, these also have important roles during embryogenesis, recent studies also suggest its role in 
spatial learning and memory formation [30]. PrP is a cell surface protein and a key player in prion disease 
[31]. This disease usually results from misfolding of prion proteins and their aggregation, further stimulating 
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misfolding in normal native proteins. This misfolding, characterized by various pathogenic mutations 
resulting either from substitution or early termination (Table 2) changes expected side chain of amino acids 
which interrupts the overall charge on the protein. This mutated protein is a major contributor to 
neurodegenerative diseases. It is also speculated that A β protein interacts with PrP receptor on the cell surface 
and causes a reduction in long-term potentiation (LTP) which is characteristic of Alzheimer’s [32, 33]. 
4. CONCLUSIONS 
Early Onset of Alzheimer’s Disease (EOAD) is inherited in an autosomal dominant fashion. The five 
primary genes found responsible for the condition are APP, PSEN1 and PSEN2, GRN and PRNP. Mutations in 
these genes, which are all located on the long arm of chromosomes are responsible for the deposition of the 
extracellular amyloid plaques. Mutations in another gene MAPT, generates intracellular tau tangles and hence 
indirectly leads to EOAD. Mutations in GRN gene lead to the development of aggregations inside the nucleus 
and the misfolding of prion protein as a result of mutations in PRNP as well as the interaction of amyloid-beta 
with prion protein are also speculated to be the major contributors. All these manifestations of the respective 
genes ultimately lead to the shrinkage of brain tissue and consequently, claiming the patient’s life. Death of the 
person primarily occurs because normal physiological functions such as breathing, swallowing etc. get impaired. 
The SNPs in these genes lead to misfolded proteins as few of these contribute to the incorporation of wrong 
amino acid, such as replacing a hydrophobic, non-polar amino acid with a hydrophilic, polar amino acid alters 
the charge on the side chain which can alter the normal protein function by changing the overall conformation of 
the protein. Such SNPs in APP gene are suspected to cause improper cleavage of amyloid protein by γ-secretase 
and presenilins. SNPs in PSEN 1 and 2 impair the function of presenilins which in turn impairs the cleavage 
activity of γ-secretase. The MAPT gene on the contrary gets hyper-phosphorylated due to mutations in genes 
encoding for kinases and phosphatases. Haploinsufficient product obtained due to mutated GRN leads to 
aggregation of TDP-43. PrP protein on the other hand gets misfolded, it further transmits this state to native 
proteins and is speculated to interact with amyloid-beta protein. Investigation of these SNPs as a risk factor to 
better understand their detrimental effect is of great relevance not only for their role as biomarkers but also as 
these provide insight into the process of EOAD progression These above-identified SNPs can prove beneficial in 
developing gene therapeutic procedures specific to Alzheimer’s. Further study and validation of the identified 
SNPs will be required to determine their clinical value and use for translation research as novel targets. 
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